A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 131,13 (+26,70%). A mediana é € 139,81 (+35,08%).
| Comprar |
22 |
| Manter |
0 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
AstraZeneca offers about $10 billion for Rhythm Pharmaceuticals
AstraZeneca has reportedly made a takeover offer of about $10 billion for Rhythm Pharmaceuticals, equivalent to $124 per share. Rhythm develops the drug IMCIVREE (active ingredient Setmelanotid) for rare causes of obesity and recorded $92.1 million in revenue in the third quarter, an increase of 29 percent from the previous quarter. Analysts see blockbuster potential for IMCIVREE, meaning AstraZeneca’s offer would strengthen its position in the metabolic field. » Mais em deraktionaer.de
Rhythm Pharmaceuticals: launch of IMCIVREE for hypothalamic obesity gains momentum
Rhythm Pharmaceuticals said at the Wells Fargo conference that the launch of IMCIVREE for hypothalamic obesity is in the “second quarter” of rollout and that there are already about 400 prescriptions from roughly 300 physicians. The company sees hypothalamic obesity (HO), Bardet‑Biedl syndrome and Prader‑Willi syndrome as strategic growth areas and reported positive Phase II data in Prader‑Willi that support Phase III planning. Rhythm stressed it is well capitalized and does not need to raise funds in the near term, but cited access to endocrinologists and the need for multiple studies in Prader‑Willi as operational challenges. The company is also developing follow‑on programs (RM‑718, Bivamelagon) to strengthen the pipeline and long‑term competitive position. » Mais em de.investing.com
Rhythm Pharmaceuticals receives Japanese approval for Imcivree to treat acquired hypothalamic obesity
Japan’s Ministry of Health, Labour and Welfare has approved Imcivree (setmelanotid) from Rhythm Pharmaceuticals for the treatment of acquired hypothalamic obesity, the first approved therapy for this form in Japan. Rhythm estimates the patient population in Japan at 5,000–8,000 and plans to launch the product before the end of 2026, depending on pricing. The approval is based on the phase‑3 TRANSCEND study, which showed a placebo‑adjusted BMI reduction of 18.8%; Imcivree is already approved in the US and the EU. » Mais em de.investing.com
Rhythm Pharmaceuticals: US launch of IMCIVREE gains momentum
Rhythm reports that the US launch of IMCIVREE for acquired hypothalamic obesity is showing strong early demand, with more than 400 therapy requests in 14 weeks and prescriptions from over 300 physicians. About two-thirds of requests were approved by quarter-end; coverage policies account for roughly 25% of commercially insured and 35% of Medicaid beneficiaries. The company holds about $330 million in cash, sufficient for roughly 24 months, and does not see a near-term need for an equity raise. Rhythm is also advancing a pipeline of MC4R agonists, plans Phase III strategies for Prader-Willi before the end of 2025, and intends to further develop bivamelagon and other programs globally. » Mais em de.investing.com
Rhythm Pharmaceuticals: positive Phase 2 data for RM-718 show 11.6% average BMI reduction
Rhythm Pharmaceuticals reports preliminary Phase 2 results for the once‑weekly MC4R agonist RM‑718 in 11 patients with acquired hypothalamic obesity. Seven patients who completed 16 weeks showed an average BMI reduction of 11.6%, stronger than comparator values for bremelanotide (bivamelagon) (10.1% after 14 weeks) and setmelanotide (10.1% after 16 weeks). There were two mild cases of local hyperpigmentation at the injection site and common adverse events such as injection‑site reactions, nausea and vomiting; two patients discontinued due to adverse events. RM‑718 is designed for high selectivity with sparing of MC1R to reduce hyperpigmentation. Rhythm will hold a conference call on Q2 financial results. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 81,34 mi | 86,07% |
| Ganho bruto | 70,59 mi | 80,89% |
| Ganho líquido | -36,52 mi | 18,98% |
| EBITDA | -32,02 mi | 21,31% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 7,24 bi |
Número de ações | 69,33 mi |
Máximo/mínimo de 52 semanas | € 110,94 - € 67,64 |
| Dividendos | Não |
Beta | 2,13 |
PER (PE Ratio) | -39,66 |
PEG (PEG Ratio) | -6,20 |
P/VC (PB Ratio) | 39,40 |
P/V (PS Ratio) | 28,40 |
Perfil da empresa
A Rhythm Pharmaceuticals, Inc., uma empresa biofarmacêutica em fase comercial, dedica-se ao desenvolvimento e à comercialização de terapêuticas para o tratamento de doenças genéticas raras de obesidade. O principal candidato a medicamento da empresa é o IMCIVREE, um potente agonista do recetor de melanocortina-4 para o tratamento da obesidade por deficiência de pró-opiomelanocortina (POMC), de pró-proteína convertase subtilisina/quexina tipo 1, de recetor de leptina (LEPR), bem como das síndromes de Bardet-Biedl e de Alström. A empresa está também a desenvolver a setmelanotida, que se encontra em ensaios clínicos de Fase II para o tratamento da obesidade por deficiência heterozigótica de POMC ou LEPR, da obesidade por deficiência do coativador 1 do recetor de esteroides, da obesidade por deficiência de SH2B1, da obesidade por deficiência do recetor MC4, da obesidade na síndrome de Smith-Magenis, de perturbações epigenéticas de POMC e de outras perturbações do MC4R. A Rhythm Pharmaceuticals, Inc. tem um acordo de investigação colaborativa com o Clinical Registry Investigating Bardet-Biedl Syndrome. A empresa era anteriormente conhecida como Rhythm Metabolic, Inc. e mudou o seu nome para Rhythm Pharmaceuticals, Inc. em outubro de 2015. A Rhythm Pharmaceuticals, Inc. foi fundada em 2008 e tem sede em Boston, Massachusetts.
| Nome | Rhythm Pharmaceuticals Inc |
| CEO | David Meeker |
| Sede | Boston,
ma EUA |
| Site | |
| Setor | Materiais básicos |
| Indústria | Produtos químicos |
| Entrada em bolsa | 09/10/2017 |
| Colaboradores | 414 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | RYTM |
Frankfurt | 1RV.F |
Düsseldorf | 1RV.DU |
München | 1RV.MU |